Is Alkermes’ Schizophrenia Data Enough To Drive Demand?

 
• By Joseph Haas

Alkermes showed that combo pill ALKS 3831 offers a better weight gain profile compared to olanzapine in schizophrenia patients, but analysts differed on whether the benefit would be great enough to drive demand against entrenched generics.

magnetic resonance image (MRI) of the brain human

More from Clinical Trials

More from R&D